SCHEMBL6961404

SCHEMBL6961404

O=C1OC(CN2CCC(c3c[nH]c4ccccc34)CC2)CN1c1ccc(F)cc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.48
HTR1A P08908 3/20 0.48
SLC6A4 P31645 3/20 0.48
DRD2 P14416 3/20 0.48
HTR7 P34969 3/20 0.48
HTR6 P50406 3/20 0.48
ADRA1D P25100 3/20 0.47
HTR2A P28223 2/20 0.47
KMT2A Q03164 1/20 0.46
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5527597 0.92 CYP2D6 (0.52) CYP2D6SLC6A4ADRA1DKMT2A
SCHEMBL6962409 0.91 CYP2D6 (0.48) CYP2D6SLC6A4ADRA1DOPRM1OPRK1
SCHEMBL6969325 0.91 DRD2 (0.55) HTR1ASLC6A4DRD2HTR7HTR6
SCHEMBL6955450 0.89 DRD2 (0.53) HTR1ASLC6A4DRD2HTR7HTR6
SCHEMBL6969178 0.88 SIGMAR1 (0.57) HTR1ASLC6A4DRD2HTR7HTR6
SCHEMBL6966928 0.88 SIGMAR1 (0.57) HTR1ASLC6A4DRD2HTR7HTR6
SCHEMBL6966376 0.88 CCR2 (0.47) CYP2D6SLC6A4ADRA1D
SCHEMBL6956812 0.85 DRD2 (0.48) HTR1ASLC6A4DRD2OPRM1OPRK1
SCHEMBL6957106 0.85 DRD2 (0.48) HTR1ASLC6A4DRD2OPRM1OPRK1
SCHEMBL6968059 0.85 DRD2 (0.48) HTR1ASLC6A4DRD2OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0964863-B1 OXAZOLIDINES AS 5-HT2A-ANTAGONISTS MERCK PATENT GMBH (DE) 2003-05-21 EP disclosed
EP-0964863-A1 OXAZOLIDINES AS 5-HT2A-ANTAGONISTS MERCK PATENT GmbH (DE) 1999-12-22 EP disclosed
WO-1998038189-A1 OXAZOLIDINES AS 5-HT2A-ANTAGONISTS MERCK PATENT GMBH (DE) 1998-09-03 WO disclosed